

INDIAN API INDUSTRY


Headwinds in remission; credit profile of Indian API companies to remain comfortable in FY2025

AUGUST 2024



Highlights





The Indian active pharmaceutical ingredients (APIs) industry is expected to grow at a compounded annual growth rate (CAGR) of 7-8% between CY2023 and CY2029, following ~8% CAGR between CY2017 and CY2023. This will be supported by steady growth in the pharmaceutical formulations industry, increasing demand for contract manufacturing with companies across the globe looking to diversify their supply chain along with greater focus on domestic sourcing.

ICRA expects revenues of its sample set companies to grow by 7-8% in FY2025, after an estimated 3-5% increase in FY2024. Moreover, with expected improvement in earnings and moderate capex plans, the credit profile of these companies will remain comfortable.



India imports ~35% of its APIs and intermediates requirement, of which China accounts for 65-70%. Dependence on China for imports of APIs for certain essential medicines remains as high as 80-100%. Even when the APIs are manufactured in India, the key starting materials (KSMs) are still primarily sourced from China.

FY2021-FY2023 was fairly challenging for the Indian API industry amidst multiple headwinds such as rising raw material costs, crude oil prices, inflationary pressures and increased energy costs in Europe, as well as heightened volatility in foreign exchange rates. However, these headwinds are in remission. That said, impact of subdued demand from some key export markets such as Europe and tensions in the Red Sea impacting supply chain and freight costs will remain monitorable.



Credit metrics for ICRA's sample* set of companies are expected to remain comfortable in FY2025, supported by marginal improvement in OPM and moderate capital expenditure (capex) plans. This is after debt coverage metrics had weakened in FY2023 and remained range-bound in FY2024.



The Government's production-linked incentive (PLI) scheme is seeing some traction, with capex of ~Rs. 3,715 crore incurred till April 2024, of the total committed capex of ~Rs. 6,500 crore.

* Aggregate of 10 companies: Aarti Drugs Limited, Anuh Pharma Limited, Covalent Laboratories Private Limited, Everest Organics Limited, Hikal Limited, NGL Fine Chem Limited, Satya Deeptha Laboratories Private Limited, Sri Krishna Pharmaceutical Limited, Supriya Lifescience Limited, and Virchow Petrochemicals Private Limited www.icra.in


AGENDA



1

Headwinds in remission; certain challenges remain monitorable







3

High dependence on China for import of APIs





Financial performance of the Indian API industry



PLI scheme to help India reducedependence on China





ICRA-rated entities in the API industry





Name	Designation	Email	Contact Number
Shamsher Dewan	Group Head	shamsherd@icraindia.com	0124 – 4545 328
Kinjal Shah	Co-Group Head	kinjal.shah@icraindia.com	022 – 6114 3442
Deepak Jotwani	Sector Head	deepak.jotwani@icraindia.com	0124 – 4545 870
Mythri Macherla	Sector Head	mythri.macherla@icraindia.com	022 – 6114 3435
Gaurav Kushwaha	Senior Analyst	gaurav.kushwaha@icraindia.com	040 – 4547 4829





Name	Designation	Email	Contact Number
L Shivakumar	Chief Business Officer	shivakumar@icraindia.com	022-61693304
Neha Agarwal	Head – Research Sales	neha.agarwal@icraindia.com	022-61693338
Rohit Gupta	Head Business Development – Infrastructure Sector	rohitg@icraindia.com	0124-4545340
Vivek Bhalla	Head Business Development – Financial Sector	vivek.bhalla@icraindia.com	022-61693372
Vinita Baid	Head Business Development – Corporate Sector - West & East	vinita.baid@icraindia.com	033-71501131
Shivam Bhatia	Head Business Development – Corporate Sector - North & South	shivam.bhatia@icraindia.com	0124-4545803
Naznin Prodhani	Head - Group Corporate Communications & Media Relations, ICRA Ltd	communications@icraindia.com	0124-4545860







© Copyright, 2024 ICRA Limited. All Rights Reserved.

All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.



Thank You!